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RUNNING TITLE:   PTEN/fos synergism in skin cancer  
 
 
 
 
 
ABBREVIATIONS:  
      
HK1.fos; HK1.ras transgenic mice expressing v-rasHa or FBJ/R v-fos 
from a modified human keratin K1 vector. 
PTENwt; ∆5PTEN wt/flx, flx transgenic mice wild type, heterozygous or 
homozygous for lox-P flanked exon 5 PTEN.  
K14.creP transgenic mice expressing RU486 responsive cre 
recombinase from a keratin K14 promoter.  
K14.cre/∆5PTENwt, wt/flx, flx                  progeny of mating 
HK1.fos/∆5PTENwt, wt/flx, flx   
SCC Squamous cell carcinoma. 
KA              Keratoacanthoma 
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ABSTRACT 
 
To investigate gene synergism in multistage skin carcinogenesis, the RU486-inducible cre/lox system 
was employed to ablate PTEN function [K14.cre/∆5PTENflx] in mouse epidermis expressing activated 
v-fos [HK1.fos]. RU486-treated HK1.fos/∆5PTENflx mice exhibited hyperplasia, hyperkeratosis and 
tumours that progressed to highly differentiated keratoacanthomas rather than carcinomas, due to re-
expression of high p53 and p21WAF levels. Despite elevated MAP kinase activity, cyclin D1/E2 over 
expression and increased AKT activity forming areas of highly proliferative, papillomatous keratinocytes, 
increasing levels of GSK3β inactivation exceeded a threshold that induced p53/p21WAF expression to 
halt proliferation and accelerate differentiation, giving the hallmark keratosis of keratoacanthomas. A 
pivotal facet to this GSK3β-triggered mechanism centred on increasing p53 expression in basal layer 
keratinocytes. This reduced activated AKT expression and released inhibition of p21WAF, which 
accelerated keratinocyte differentiation, as indicated by unique basal layer expression of differentiation-
specific keratin K1, alongside premature filaggrin and loricrin expression. Thus, fos synergism with 
PTEN loss elicited a benign tumour context where GSK3β-induced, p53/p21WAF expression 
continually switched AKT-associated proliferation into one of differentiation, preventing further 
progression. This putative compensatory mechanism required the critical availability of normal p53 
and/or p21WAF otherwise deregulated fos, Akt and GSK3β associate with malignant progression. 
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INTRODUCTION 
 
PTEN is a tumour suppresser gene attracting significant interest given its high mutation frequency in 
human cancers and its roles in apoptosis/proliferation via negative regulation of AKT/PKB activity 
(Downward, 2004; Parsons, 2004). Consistent with the direct protein-protein interactions that regulate 
p53 function (Freeman et al., 2003; Lei et al., 2006), PTEN mutation in Cowden Disease patients results 
in cancer predisposition (Liaw et al., 1997) associated with cutaneous hyperkeratosis (Fistarol et al., 
2002), suggesting that roles in keratinocyte differentiation can be added to PTEN activities essential for 
normal development. In transgenic mice, PTEN hetrozygotes (Stambolic et al., 2000) or conditional 
knockouts (Li et al., 2002; Suzuki et al., 2003) exhibit neoplasia associated with increased anti-
apoptotic AKT activities, cell migration/adhesion anomalies (Masahito et al., 1998; Subauste et al., 
2005) and cell cycle control failure (Di Cristofano et al., 2001; Weng et al., 2001).  In addition, recent 
models demonstrate that GSK3β, which integrates WNT and β-catenin signalling (Karim et al., 2004), 
co-operates with PTEN loss in prostate carcinogenesis (Mulholland et al., 2006) when p53 is also 
compromised (Chen et al., 2005), whilst bladder models identified compensatory roles for p21WAF that 
countered initial PTENnull-mediated hyperplasia (Yoo et al., 2006). 
 
Multistage skin carcinogenesis studies implicate these molecules also; roles for p53 are well established  
(Brash, 2006), if sometimes paradoxical (Greenhalgh et al., 1996; Wahl, 2006), as are those for p21WAF 
(Topley et al., 1999; Devgan et al., 2006). In classic two-stage DMBA/TPA chemical carcinogenesis, 
AKT activation and GSK3β inactivation typically correlate with tumour progression (Leis et al., 2002; 
Segrelles et al., 2006) and employing conditional PTEN knockouts, DMBA-initiated c-rasHa activation 
achieved increased malignancy following TPA promotion (Suzuki et al., 2003). However, two-stage 
chemical carcinogenesis employing heterozygous PTEN knockouts identified a mutual exclusivity 
between PTEN loss and c-rasHa activation (Mao et al., 2004). This was partly resolved on finding that 
ras
Ha
 synergism with PTEN loss (∆5PTEN, Li et al., 2002) gave benign papillomas, but required TPA for 
malignant conversion, which involved a separate ∆5PTEN-mediated mechanism of cell cycle 
deregulation that superseded initial ∆5PTEN/rasHa synergism  (Yao et al., 2006).  
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Given that the oncogene fos is a major effecter of TPA promotion (Schlingemann et al., 2003) and co-
operates with rasHa during papillomatogenesis and malignant conversion (Greenhalgh et al., 1990, 1993a, 
1995; Seaz et al., 1995), this study investigated whether activated fos would cooperate with PTEN loss in 
papillomatogenesis and drive this rasHa-independent, ∆5PTEN-mediated mechanism of malignant 
progression. Indirect links between FOS and PTEN deregulation already exist, as ∆5PTEN could 
substitute for activated rasHa during TPA promotion (Yao et al., 2006) and c-fos-mediated photo-
carcinogenesis associates with both AKT activation and GSK3β inactivation (Gonzales and Bowden, 
2002).  Further, UV-B-mediated p53 mutation and subsequent PTEN loss induces AP-1 expression 
(Wang et al., 2005) whilst in reverse, PTEN specifically targets c-fos expression via AKT signalling, to 
down regulate AP-1 activity (Koul et al., 2007).  
 
Direct co-operation between activated fos [HK1.fos] and inducible PTEN loss in adult skin  [∆5PTEN] 
resulted in an unanticipated keratoacanthoma [KA] aetiology, rather than malignant progression to 
squamous cell carcinoma [SCC]. Analysis of the underlying mechanism demonstrated that 
compensatory p53 and p21WAF expression prevented progression via switching highly mitotic, 
papilloma keratinocytes into a programme of accelerated differentiation, manifest by unique, novel 
basal layer expression of early differentiation-specific keratin K1. This p53/p21WAF expression profile 
was apparently induced by progressively increasing levels of GSK3β inactivation.  In addition pivotal 
roles for AKT were identified, where p53/p21WAF-mediated reduction of AKT activity in basal layer 
keratinocytes of benign tumours appeared to be a key facet underlying the switch in progression to 
KA, not SSC. 
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RESULTS 
 
 
PTEN loss co-operates with HK1.fos expression to elicit keratoacanthomas with atypical 
keratinocyte differentiation. 
Investigation of PTEN loss and fos activation in skin carcinogenesis was achieved by employing 
topical RU486 application to activate cre recombinase (K14.creP, Berton et al., 2000) and ablate 
loxP-flanked PTEN exon 5 (∆5PTEN; Li et al., 2002) in proliferative basal layer keratinocytes and 
hair follicles, due to the expression specificity of the K14 promoter (Yao et al., 2006). These mice 
were bred to HK1.fos mice that exclusively express epidermal v-fos in approx 25-30% transit 
amplifying cells and all suprabasal keratinocytes by virtue of a truncated, human keratin 1 based 
vector (HK1.fos, Greenhalgh et al., 1993b) but not hair follicles nor internal epithelia. All RU486-
treated HK1.fos/∆5PTENflx mice [Fig. 1], exhibited bilateral ear tumours by 6-7 weeks [n = 55; 
produced over a 2.5yr period], which rapidly progressed to form keratoacanthomas [KAs]. KA 
aetiology in treated HK1.fos/∆5PTENflx/wt heterozygotes [n = 35] was slower and required an ear-tag 
wound promotion stimulus. Treated HK1.fos [PTENwt] controls developed wound-dependent ear 
hyperplasia by 3-4 months and papillomas after long latency [> 12 mo (Greenhalgh et al., 1993b)], 
whilst RU486-treated K14.cre/∆5PTENflx siblings exhibited epidermal hyperkeratosis without 
spontaneous papillomas (Yao et al., 2006). Transgene expression/ablation analysis [Supp. Data: Fig. 
1S] confirms permanent ablation of PTEN exon 5 following RU486 treatment, and demonstrated 
HK1.fos expression in normal appearing skin, which appeared elevated in KAs, consistent with their 
increased differentiation and anomalous murine K1 expression in proliferative basal layers [below].   
 
The KA outcome of fos cooperation with PTEN contrasts to induction of malignant conversion in co-
operation with rasHa [Greenhalgh et al., 1990; 1995; Saez et al., 1995] or TPA-mediated, i.e. fos-
associated (Schlingemann et al., 2003), conversion of HK1.ras/∆5PTEN papillomas (Yao et al., 2006). 
This difference may centre on inherent abilities of an epidermis to cope with specific genetic insults as 
reflected by the histotypes produced.  The histotype of HK1.fos skin [Fig. 1A] was indistinguishable 
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from normal despite HK1.fos expression [supp data, Fig. 1: lane 5] that gave an underlying doubling 
in mitotic index (below Fig. 3; Greenhalgh et al., 1993b). Hence, prior to wound promotion, as v-fos 
potentiates the functions of c-fos, HK1.fos-induced proliferation was counterbalanced via c-fos 
functions in regulation of keratinocyte turnover and/or differentiation (Angel et al., 2001; Mehic et al., 
2005), which also involved down regulation of AKT activity [below]. Similarly, as observed in cancer 
prone Cowden disease patients (Stambolic et al., 2000; Fistarol et al., 2002), treated 
K14.cre/∆5PTENflx epidermal histotypes exhibited a relatively mild hyperplasia dominated by 
hyperkeratosis [Fig. 1B], with blooms of “ghost” cells indicative of incomplete stratification. This 
suggests that a proliferative response due to PTEN loss was rapidly translated into hyperkeratosis to 
eliminate potentially neoplastic cells at an early stage and this also involved AKT activation in 
regulation of differentiation [below] (Calautti et al., 2005). Furthermore, ∆5PTEN expression would 
compromise PTEN-mediated functions in cell-cell adhesion and cell-matrix interactions (Masahito et 
al., 1998; Subauste et al., 2005) that threaten epidermal barrier function, hence this hyperkeratotic 
response may also conscript epidermal homeostasis mechanisms in order to maintain epidermal 
integrity.  
 
At approx 5-6 mo, when HK1.fos mice displayed only wound-dependent hyperplasia/early 
papillomatogenesis [Fig 1C], HK1.fos/∆5PTENflx mice possessed mature KAs [Fig. 1D].  These 
tumours comprised two distinct histotypes: one of significant differentiation, with “fronds” of 
keratinocytes interspaced within massive areas of keratosis; and a second papillomatous area comprising 
highly proliferative keratinocytes, similar to late stage, aggressive papillomas or possibly carcinoma in 
situ.  Furthermore, while keratinocyte differentiation in HK1.fos phenotypes displayed an ordered nature 
with sequential expansion of each cellular compartment [Fig. 1C], keratotic, but not papillomatous, 
HK1.fos/∆5PTENflx KA histotypes, displayed a distinctly disordered differentiation pattern [Fig. 1E-G]. 
Here cornified and granular cells co-existed alongside proliferative basal cells, culminating in the 
appearance of micro-cysts [Fig. 1E, G: arrows] and a prominent stratum luciduim [Fig. 1F: arrows] 
indicative of incorrect cornification. This confusion of differentiated and proliferative cell sub-types in 
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each epidermal compartment suggests that HK1.fos-∆5PTENflx keratinocytes received abruptly 
conflicting proliferation and differentiation signals in this keratotic/differentiated histotype.  
 
Premature differentiation marker expression in keratoacanthomas associates with reduced 
progression marker expression and decreased proliferation. 
 
Tumours were analysed for expression of keratin K1, an early-stage differentiation marker, and late-
stage differentiation markers filaggrin and loricrin, all proteins which typically become lost during 
carcinogenesis, and also for keratin K13, a simple epithelia keratin, employed as a marker of 
papilloma progression, which typically becomes uniform prior to malignant conversion (Greenhalgh 
et al., 1995).  As observed previously, HK1.fos papillomas exhibit a delay in the onset of K1 
expression due to expansion of the proliferative basal layer compartment [Fig. 2A, indicated by the 
K14 keratin counterstain]. This result was also observed in papillomatous HK1.fos/∆5PTENflx KA 
histotypes [not shown], however highly differentiated HK1.fos/∆5PTENflx KA histotypes exhibited 
novel, K1 expression in the proliferative basal layers. K1 expression was quite strong, given the lack 
of yellow colour from [red] K14 co-expression, although K14 expression itself remained unchanged 
[see Fig. 3]. Typically, AP1-regulated keratin K1 is expressed as differentiating keratinocytes commit 
to leave the basal layer (Rothnagel et al., 1993) and this result suggests that HK1.fos/∆5PTENflx 
keratinocytes accelerated their commitment to differentiation in these keratotic areas.   
   
The premature expression profiles of loricrin and filaggrin [Fig. 2B, C] also indicated accelerated 
differentiation. In HK1.fos papillomas, AP-1-regulated loricrin expression, a major component of 
granular cells, remained restricted to the granular compartment, where c-fos is also highly expressed 
(Greenhalgh et al., 1993b; Mehic et al., 2005). Conversely, HK1.fos/∆5PTENflx KAs exhibited 
premature elevated, suprabasal loricrin expression in areas of atypical differentiation, particularly 
highlighting the micro-cysts [Fig. 2B]. Similarly, filaggrin expression, another AP-1-regulated 
8 
component of cornification, with critical functions in barrier maintenance (Palmer et al., 2006), was 
reduced in HK1.fos papillomas, whereas HK1.fos/∆5PTEN KAs expressed early, high filaggrin levels 
in suprabasal and occasional basal keratinocytes [Fig. 2C]. With respect to keratin K13, HK1.fos 
papillomas [Fig. 2D] exhibited the focal/patchy K13 expression profile typical of benign tumours 
(Greenhalgh et al., 1993b). However, while early HK1.fos/∆5PTENflx tumours and the proliferative, 
papillomatous histotypes of KAs exhibited focal K13 expression, the differentiated regions lost K13 
expression [Fig. 2D]. Thus, a hyperproliferative, K13-positive papillomatous keratinocyte population 
differentiated into a quiescent, K13-negative population and suggests that the temporal event(s) that 
switched progression to KA occurred at the overt, benign tumour stage and not in pre-neoplastic 
hyperplasia.  
 
BrdU labelling data also support this idea. As shown in Fig. 3, acquisition of each additional mutation 
resulted in sequential increases in mitotic index [labelled nuclei/mm basement membrane], culminating 
in very high levels in HK1.fos/∆5PTENflx papillomatous histotypes, until suddenly halted in the 
differentiated regions. Normal appearing HK1.fos epidermis possessed a mitotic index [10.1+/
-
 2.1] 
approximately double that of non-transgenic adult epidermis [4.7+/
-
 3.0], which in K14.cre/∆5PTENflx 
genotypes [13.7+/
-
 3.6] gave mild hyperplasia. Additional doubling of mitotic index occurred in 
HK1.fos/∆5PTENflx skin [26.1 +/
-
 5.7] to levels observed in HK1.fos papillomas [27.2 +/
-
 7.1, Fig. 3B], 
whilst KA keratinocytes possessed a very high mitotic index [90.2 +/
-
 17.6;] comparable to aggressive 
SCCs, with extensive supra-basal BrdU-labelling [Fig. 3B], whereas keratinocytes of differentiated 
histotypes possessed a significantly reduced mitotic index [36.6 +/
-
 6.7; p = < 0.0001], although this 
remained higher than that of typical HK1.fos papillomas [p = 0.001 Students t test]. Thus, BrdU 
labelling indicated a potent counter to hyperproliferation arose after benign tumour formation, which 
inhibited further progression. 
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HK1.fos/∆5PTEN KAs express high levels of normal p53 whereas control HK1.fos and 
K14.cre/∆5PTEN phenotypes loose p53 expression. 
 
Given the close relationship between PTEN and p53 regulation (Freeman et al., 2003; Lei et al., 2006; 
Wang et al., 2005), p53 status during HK1.fos/∆5PTENflx KA aetiology was determined by western 
analysis of normal epidermis, pre-neoplastic phenotypes and tumours taken from separate animals 
[Fig. 4]; or from the same animals [Fig. 5], to compare KAs with similar keratosis/papilloma ratios, 
and/or age-matched littermate control phenotypes. Hyperkeratotic K14.cre/∆5PTENflx epidermis 
exhibited little detectable p53 expression [Figs 4, 5: HK lanes] compared to normal epidermis [Fig. 4: 
aN, N, NE lanes]. Similarly, hyperplastic HK1.fos epidermis and papillomas also lost p53 expression 
and p53 levels were undetectable in “normal” appearing HK1.fos skin [Figs 4, 5: N, PAP, HP lanes]. 
This latter result was consistent with the doubled mitotic index [above] but inconsistent with the 
normal histotype. On rare occasions low-level p53 expression was recorded in HK1.fos phenotypes 
due to inflammation or presence of anagen follicles [Fig. 4,: aN lane] where HK1.fos was not 
expressed.  
 
Conversely, in both homozygous and heterozygous ∆5PTEN animals, significantly high levels of p53 
expression were recorded in HK1.fos/∆5PTEN KAs [Figs. 4, 5: KA lanes]. Expression levels varied 
amongst randomly selected KAs [Fig. 4] but were usually high, and p53 expression increased with 
KA maturity/size [Fig. 5], e.g. heterozygous HK1.fos/∆5PTENflx/wt KAs developed less rapidly and 
typically possessed lower increases in p53 expression when analysed alongside the faster growing, 
mature KAs of homozygotes [Fig. 4:  #8898 vs. #9593 KAs]. A result also recorded on comparison of 
larger, wound-promoted ear-tagged vs. untagged ear KAs from the same animals [Fig. 5, lanes: KAT 
vs. KA]. In addition, pre-neoplastic HK1.fos/∆5PTENflx or -wt/flx epidermis expressed low-level p53 
[Fig. 4, lanes: HK #8898, #9593; Fig. 5, HK lanes: 5,6,9] suggesting p53 expression was an early 
feedback response to HK1.fos synergism with PTEN loss. This high p53 expression in benign tumours 
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was consistent with the reduced BrdU labelling in keratotic, differentiated KA histotypes compared to 
high labelling indices of papillomatous regions, and together with decreased K13 tumour marker 
expression, elevated p53 would inhibit further tumour progression. This idea was further supported by 
sequence analysis of p53 cDNAs from HK1.fos/∆5PTENflx KAs [n = 5], which found full-length 
transcripts without detectable mutation or alternate splicing [not shown], hence normal p53 tumour 
suppressor functions appeared intact (Nister et al., 2005). HK1.fos/∆5PTEN KAs also lacked 
spontaneous c-rasHa activation (Corominas et al., 1989; Greenhalgh et al., 1990, 1995; Lieu et al., 1991) 
[n = 5; not shown].  Thus, high expression of normal p53 in KA aetiology may be rendered impotent 
by rasHa activation leading to SCC, an idea currently under investigation in triple 
HK1.ras/fos/∆5PTENflx mice.  
 
Regulation of AKT activation is a pivotal target of tumour progression and epidermal 
homeostasis. 
 
Consistent with loss of PTEN phosphatase function following ablation of exon 5 (Parsons, 2004), 
levels of activated AKTser473 phosphorylation [p-AKT] rose in RU486-treated K14.cre/∆5PTENflx 
epidermis [Fig. 4: HK lanes]. HK1.fos/∆5PTENflx KAs also exhibited increased p-AKT expression 
[Figs 4,5], however levels were not as high as expected and, compared to total AKT expression levels, 
p-AKT expression varied significantly with the degree of keratosis vs. hyperproliferation [Fig. 4, 
KA*] or KA size/maturity [Fig. 4, lanes: #8898 and #9593]. Analysis of histology-matched KAs [Fig. 
5] found only moderate increases in p-AKT expression compared to hyperplastic epidermis taken 
from the same animal. Moreover, p-AKT levels in pre-neoplastic HK1.fos/∆5PTENflx epidermis were 
consistently lower than age-matched K14.cre/∆5PTENflx littermate epidermis [Fig. 5, 
K14.cre/∆5PTENflx HK lanes: 1, 2; vs. HK1.fos/∆5PTENflx HK lanes: 5,6, 9]. This suggests that p-
AKT inhibition was a target of the early, low–level p53 feedback response, consistent with PTENnull 
prostate carcinogenesis, where NKX3.1 inhibits p-AKT to stabilise p53 expression (Lei et al., 2006). 
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The fact that the p-AKT expression increase in HK1.fos/∆5PTENflx KAs was lower than that of 
comparable rasHa/∆5PTEN synergism (Yao et al., 2006) was also consistent with inhibition of AKT 
by high p53 levels. However, this moderate p-AKT expression profile masked a significant expression 
level in HK1.fos/∆5PTENflx papillomatous areas as detected by immunohistochemical analysis [below, 
Fig. 6; Supp data: Fig. 2s], suggesting that AKT played significant roles in papillomatogenesis and 
continuation of this activity was essential for further malignant progression (Segrelles et al., 2006; 
Yao et al., 2006).  
 
An earlier role for AKT regulation was identified in HK1.fos “normal” appearing or hyperplastic 
epidermis, which exhibited little p-AKT expression compared to total AKT expression levels, and 
levels remained relatively low until overt papillomas appeared [Fig. 4 HK1.fos lanes: N, HP, P; Fig. 5, 
lanes N, P]. Thus, p-AKT down regulation maybe an element of epidermal resistance to early 
carcinogenesis. This observation may explain the delay in papilloma appearance and the longstanding 
puzzle that a p53-negative, HK1.fos epidermis exhibited a normal histotype, despite a mitotic index 
that gave hyperplasia/hyperkeratosis in K14.cre/∆5PTENflx skin [Figs 1,3]. Given the direct links 
between fos and PTEN (this study; Koul et al., 2007; Wang et al., 2006), coupled to the intimate 
interactions between p53 and PTEN (Freeman et al., 2003), HK1.fos-mediated p53 loss maybe 
countered in part by a PTEN-mediated feedback involving p-AKT down regulation, which facilitates 
keratinocyte turnover and differentiation (Angel et al., 2001; Calautti et al., 2005) and this is under 
investigation. Hence HK1.fos phenotypes required a wound-promotion stimulus, eliciting high p-ERK 
1/2 and increased cyclin D1/E2 expression [below], to antagonise/interdict such putative 
countermeasures and restore p-AKT expression in HK1.fos papillomas [Figs 4,5 lanes: PAP]. Adding 
further complexity to AKT oncogenicity, in p53-negative K14.cre/∆5PTENflx epidermis, where AKT 
would be released from PTEN control, elevated p-AKT expression [Fig. 4, HK lanes; Fig. 5: HK lanes 
1,2] was accompanied by a rapid translation of hyperplasia into hyperkeratosis [Fig. 1B], as observed 
in Cowdens Disease, but no papillomas [unless promoted by TPA (Yao et al., 2006)], demonstrating 
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that AKT regulation in keratinocyte differentiation can dictate differing outcomes depending on the 
context(s) of gene expression.  
 
HK1.fos/∆5PTEN keratoacanthoma aetiology identifies significant roles for GSK3β inactivation. 
 
Key insights into HK1.fos/∆5PTEN KA development derived from analysis of GSK3β expression 
(Karim et al., 2004), a gene functionally inactivated by several oncogenes including AKT, via 
phosphorylation at serine 9 [p-GSK3β] (Parsons, 2004). In being an AKT target, elevated levels of p-
GSK3β were displayed by hyperkeratotic K14.cre/∆5PTENflx epidermis [Fig. 4, HK lanes], and 
normal or early hyperplastic HK1.fos epidermis exhibited reduced p-GSK3β expression following p-
AKT down regulation [Fig. 4, lanes: N, HP]. However, HK1.fos papillomas expressed moderate p-
GSK3β levels higher than that attributable to p-AKT expression [Figs. 4, 5: PAP lanes], and 
increasing HK1.fos hyperplasia displayed low-level p-GSK3β when p-AKT remained undetectable 
[Supp data: Fig. 3S]. As HK1.fos papillomatogenesis required wound-promotion, this fos-associated 
p-GSK3β inactivation uncoupled from AKT activity, may derive from high levels of ERK1/2 
expression or increased cyclins [below, Figs 4, 5: PAP lanes].  
 
 Inactivation of GSK3β was found to be instrumental to the eventual KA outcome, as increased p-
GSK3β expression correlated to elevated p53 expression [Figs 4, 5]. This association was initially 
unclear due to differing keratosis/papilloma ratios [Fig. 4, lanes: KA vs. KA*], however analysis of 
KAs with similar keratosis/papilloma ratios consistently expressed high levels of inactivated p-
GSK3β, concomitant with high p53, but not p-AKT expression, which remained only similar to that of 
K14.cre/∆5PTENflx epidermis [Fig. 5: KA vs. HK lanes]. Hyperplastic HK1.fos/∆5PTENflx epidermis 
also possessed moderately elevated p-GSK3β levels, associated with low-level p53 expression, again 
uncoupled from that of p-AKT, which was down regulated [Fig. 5 lanes: HK 5,6,9]. The moderate p-
GSK3β expression associated with low-level p53 expression in HK1.fos/∆5PTENflx epidermis, 
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coupled to the major increases in p-GSK3β expression alongside the burst of p53 expression in KAs, 
suggests that inactivation of GSK3β function triggered p53 re-expression (Ghosh and Altieri, 2005). 
Furthermore, the apparent burst of p53 and abrupt reduction in keratinocyte proliferation that 
prevented further progression, required a high threshold level of GSK3β inactivation and this may 
have been achieved from the moderate, AKT independent p-GSK3β expression HK1.fos/∆5PTENflx 
observed in early preneoplastic hyperplasia [above] coupled to that derived from increasing p-AKT 
activity in papillomatous areas [Fig. 5: KA lanes].   
 
HK1.fos/∆5PTENflx KAs exhibit novel p21WAF expression deregulated cell cycle control and 
elevated MAP kinase signalling.  
 
The mechanism underlying KA aetiology was extended to investigate cell cycle deregulation via 
western analysis of p21WAF, cyclin D1 and E2 expression together with MAP kinase signalling via 
analysis of ERK 1/2 activation. Analysis of p21WAF was doubly attractive, since p21WAF possesses 
roles in keratinocyte differentiation (Topley et al., 1999) separate to that of cell cycle regulation 
(Devgan et al., 2006) and can be an early response to PTEN loss (Yoo et al., 2006). All 
HK1.fos/∆5PTENflx KAs exhibiting p-GSK3β hyper-inactivation and high p53 expression, also 
exhibited novel, high p21WAF expression levels [Fig. 5: KA lanes]. However, unlike induction of low-
level p53 expression by moderate p-GSK3β expression in HK1.fos/∆5PTENflx hyperplasia [Figs 4, 5], 
below the high GSK3β inactivation threshold, p21WAF expression was not induced [Fig. 5, lanes: HK, 
P, vs. KA]. Further, p53 negative HK1.fos papillomas and K14.cre/∆5PTENflx phenotypes, with lower 
GSK3β inactivation levels were negative for p21WAF expression [Fig. 5]. Thus p21WAF expression was 
specific to mature KAs, and the data suggest that p21WAF expression arose following induction of p53, 
possibly as a consequence of p53-mediated down regulation of AKT activity [below (Zhou et al., 
2001)]. Moreover, this temporal p21WAF expression indicated that the critical changes in progression 
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occurred at the overt benign tumour stage, a result consistent with the K13/BrdU labelling data and 
previous roles for p21WAF associated with inhibition of malignant conversion (Topley et al., 1999).   
 
Analysis of cyclins D1, E2 and MAP Kinase signalling in HK1.fos/∆5PTENflx KAs [Figs. 4, 5] was 
also consistent with the idea that persistent keratinocyte hyperproliferation was continually switched 
into differentiation. Increasing hyperplasia in HK1.fos/∆5PTENflx epidermis was reflected by elevated 
cyclin expression [Fig. 5: HK lanes 5,6,9] alongside increased p-ERK 1/2 expression [Fig. 4: HK 
lanes], which were retained at moderate levels in mature KAs, despite the p53/p21WAF expression 
profile, due to the hyperproliferation observed in papillomatous areas [Fig. 5: KA lanes]. Thus, in 
HK1.fos/∆5PTENflx tumour aetiology, induction of both p53 and p21WAF were able to halt excessive 
proliferation, unlike activated rasHa cooperation with PTEN loss, where p53 remained lost and strong 
cyclin D1/E2 over expression was associated with AKT-mediated progression to carcinoma (Yao et 
al., 2006). 
 
Analysis of control phenotypes [Figs 4, 5] found that normal HK1.fos epidermis exhibited a small 
elevation in cyclin D1 but not E2, and slightly elevated p-ERK 1/2 expression, compared to total ERK 
1/2 levels [Figs. 4, 5: N lanes] (Karin, 1995), consistent with its doubled mitotic index.  HK1.fos 
papillomas [Fig. 5: PAP lane] exhibited increased cyclin D1 and E2 expression (Bamberger et al., 
2001), together with very high levels of activated p-ERKs 1/2 expression [Fig. 4 lanes: P, HP, N], 
which suggested that MAP Kinase signalling during wound-promoted HK1.fos papillomatogenesis 
facilitated escape from AKT-linked countermeasures [above] to restore p-AKT activity (Segrelles et 
al., 2006). In K14.cre/∆5PTENflx epidermis, similar small elevations in both cyclins D1 and E2 (Di 
Cristofano et al., 2001; Weng et al., 2001) were recorded, associated with promotion from ear tagging 
[Fig. 5, lanes: HKT vs. HK], alongside increased p-ERK 1 and 2 levels [Fig. 4, end panel: HK lanes]; 
all consistent with p-AKT regulation of PI3 Kinase and interactions with MAPK signalling (Parsons, 
2004; Downward, 2004).  
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Immunohistochemical analysis identified p-GSK3β-associated p53/p21WAF expression and down 
regulation of p-AKT activity in basal layer keratinocytes.  
 
To further clarify these molecular interactions, the in situ expression profiles of p53, p21WAF, p-
GSK3β and p-AKT were determined via immunohistochemical analysis of differentiated, transitional 
and papillomatous HK1.fos/∆PTENflx KA histotypes [Fig. 6. See also Supp. data: Fig. 2S].  Analysis 
of HK1.fos and K14.cre/∆PTENflx control phenotypes are given in Supp. data: Fig. 3S. In all 
differentiated KA histotypes, p53 was strongly expressed throughout each epidermal compartment, 
including proliferative basal layer keratinocytes [Fig. 6A].  In transitional areas, initially p53 
expression was low and predominantly suprabasal, but expression became increasingly stronger and 
appeared in the basal layer [Fig. 6B; Supp data:  Fig. 2S]. Conversely, papillomatous areas possessed 
little detectable p53 protein [Fig. 6C; Supp data: Fig. 2S]. However, low-level, suprabasal/granular 
p53 expression was observed in hyperplastic HK1.fos/∆PTENflx epidermis and occasional 
papillomatous areas, both associated with elevated, suprabasal expression of p-GSK3β [not shown]. 
Differentiated KA histotypes exhibited strong p21WAF expression in all layers [Fig. 6D; Supp. data: 
Fig. 2S], and again this began in transitional histotypes with a low-level suprabasal and cytoplasmic 
p21WAF expression profile, until elevated expression appeared in the nuclei of basal cells associated 
with increased differentiation [Fig. 6E], prior to becoming strong and uniform in all compartments. 
This expression profile appeared to trail the wave of high p53 expression [Supp data: Fig. 2S], as all 
papillomatous KA histotypes always lacked detectable p21WAF expression, even if p53 was detectable 
[Fig. 6F; Supp. data: Fig. 2S], and p21WAF was undetectable in hyperplastic HK1.fos/∆PTENflx 
epidermis [not shown] or HK1.fos and K14.cre/∆PTENflx control phenotypes [Supp. data: Fig. 3S]. 
Given the roles for p21WAF in epidermal differentiation (Topley et al., 1999), this basal layer 
expression of p21WAF would be consistent with the premature commitment of HK1.fos/∆PTENflx 
keratinocytes to terminal differentiation, as indicated by novel, basal layer K1 expression [above], 
whilst the confused, atypical nature of epidermal differentiation maybe due to continued, p21WAF 
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expression in the suprabasal/granular layers when normally p21 expression shuts down (Devgan et al., 
2006).  
 
Expression of p-GSK3β in differentiated KA regions paralleled this p53/p21WAF profile, with strong, 
expression in the basal layers and each epidermal compartment [Fig. 6G]. In transitional histotypes, 
uniform p-GSK3β expression preceded basal p53/p21WAF expression [Fig. 6H; Supp data: Fig. 2S], as 
p-GSK3β already appeared earlier in the suprabasal layers of papillomatous KA histotypes [Fig. 6I; 
Supp. data: Fig. 2S] and hyperplastic HK1.fos/∆PTENflx epidermis [not shown]. In HK1.fos/∆PTENflx 
epidermis, moderate suprabasal p-GSK3β expression was associated with supra-basal p53 expression, 
prior to p53 loss in papillomatogenesis, and this could be observed in occasional papillomatous areas 
also, suggesting the beginnings of a counter to hyperproliferation, but this was insufficient to induce 
p21WAF.  Thus, increasingly high and basal layer expression of p-GSK3β in the transitional areas 
induced a corresponding increase in basal layer expression of first p53, to halt proliferation, and later 
p21WAF to increase differentiation rate. 
 
Analysis of p-AKT in HK1.fos/∆PTENflx KAs [Fig. 6J-L] demonstrated a reverse of these expression 
profiles, as differentiated or transitional p53/p21WAF-positive areas expressed decreasing levels of p-
AKT [Fig. 6J, K]. Conversely, p53/p21WAF-negative papillomatous histotypes exhibited high p-AKT 
expression levels [Fig. 6L], a result masked in western analysis, as p-AKT expression faded with 
increasing differentiation and KA maturity [Fig. 6J; Supp data: Fig. 2S]. Moreover, p-AKT expression 
consistently appeared in the basal layers of papillomatous areas [Fig. 6L], suggesting that AKT 
activity helped provide a continuous supply of hyperproliferative keratinocytes, hence the lack of KA 
regression; while in increasingly p53/p21WAF positive transitional areas, p-AKT expression became 
suprabasal [Fig. 6K], following the appearance of high basal layer p53 expression [Fig. 6B], that 
culminated in reduced, suprabasal p-AKT expression in differentiated histotypes [Fig. 6J]. Analysis of 
consecutive sections found that co–expression of p21WAF and p-AKT appeared particularly 
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antagonistic, with high p-AKT expression being almost mutually exclusive to that of p21WAF [Fig. 
6E,K]; and in composite micrographs, uniform increasing p21WAF expression paralleled down 
regulation of p-AKT [Supp data: Fig. 2S]. Collectively, it may be that p53-mediated reduced p-AKT 
expression in basal keratinocytes was instrumental to releasing p21WAF activity (Zhou et al., 2001) and 
the commitment to premature differentiation (Topley et al., 1999).  
 
Analysis of HK1.fos phenotypes reflected the western data, with little p-AKT, p53 or p21WAF 
expression in hyperplastic epidermis or papillomas, whilst HK1.fos papillomas/late-stage hyperplasia 
exhibited the low-level, suprabasal p-GSK3β expression profile observed in HK1.fos/∆PTENflx 
epidermis [Supp. data: Fig. 3S]. RU486-treated K14.cre/∆PTENflx epidermis also lacked p53 and 
p21WAF, but consistent with the K14.creP expression profile and loss of phosphatase activity, 
displayed p-AKT expression together with p-GSK3β expression in basal layers and follicles [Supp. 
data: Fig. 3S]. 
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DISCUSSION 
 
HK1.fos/∆5PTENflx mice demonstrated direct co-operation between inducible PTEN loss and 
activated FOS expression, which resulted in preneoplastic hyperplasia/hyperkeratosis and a rapid 
development of overt benign tumours that progressed to KA not SCC. Importantly, this study found that 
in the context of HK1.fos/∆5PTENflx benign tumours, significant re-expression of p53 and p21WAF, 
previously lost in control phenotypes, now inhibited further malignant progression. This 
compensatory p53/p21WAF expression profile was triggered by increasing levels of GSK3β 
inactivation (Ghosh and Altieri, 2005), which inhibited p-AKT activity in basal layer keratinocytes 
(Lei et al., 2006) to reduce proliferation, as indicated by BrdU labelling, and initiate p21WAF-mediated 
differentiation (Devgan et al., 2006; Topley et al., 1999; Zhou et al., 2001), associated with novel 
basal layer expression of keratin K1 and premature loricrin and filaggrin expression. This potential 
sentinel mechanism, deployed at the benign tumour stage and critically dependent on normal p53 and 
p21WAF functions, was able to continually block malignant progression via switching keratinocyte 
hyperproliferation into differentiation, resulting in the hallmark keratosis of KA. 
 
 This outcome of KA rather than SCC, was in sharp contrast to the high frequency of TPA-promoted 
[i.e. fos-associated (Schlingemann et al., 2003)] carcinomas observed in HK1.ras/∆5PTENflx mice 
(Yao et al., 2006) or rasHa-activated, DMBA/TPA carcinogenesis studies involving PTEN knockouts 
(Mao et al., 2004; Suzuki et al., 2003). Nonetheless, early HK1.fos/∆5PTENflx synergism was 
consistent with promotion roles assigned to fos (Greenhalgh et al., 1993a, 1993b; Saez et al., 1995) and 
the fact that PTEN loss could act as a weak initiator for TPA promotion (Yao et al., 2006). Indeed, whilst 
rapid, papillomatogenesis presented few surprises, as HK1.fos-∆5PTENflx apparently substituted for 
ras
Ha
 activation observed in previous rabbit ear models of KA (Corominas et al., 1989), exhibiting 
moderate elevation in MAP Kinase signalling (Parsons, 2004; Downward, 2004; Karin, 1995) and 
over expression of cyclin D1 (Bamberger et al., 2001; Burnworth et al., 2006) or cyclin E2 (Di 
Cristofano et al., 2001; Weng et al., 2001). Incremental increases in keratinocyte proliferation 
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culminated in very high BrdU labelling indices in papillomatous KA histotypes, with typical delays in 
expression of differentiation markers and the appearance of focal keratin K13 expression, an early 
marker of tumour progression. (Greenhalgh et al., 1995). However, the initial appearance of K13 and 
high BrdU labelling abruptly diminished in transitional and differentiated KA histotypes, indicating a 
potent inhibition of proliferation appeared at the benign tumour stage which accelerated terminal 
differentiation rather than apoptosis, given the premature expression of keratin K1, loricrin and 
filaggrin. The resulting disorder to keratinocyte differentiation, also observed in cyclin D1–
transformed HaCaT keratoacanthomas (Burnworth et al., 2006), highlighted a clash between 
proliferative/oncogenic and compensatory/differentiation pathways. Here novel, basal layer 
expression of keratin K1 was perhaps a major contributor to the KA outcome, as it not only indicated 
a sudden, accelerated commitment to differentiation (Rothnagel et al., 1993) but also, basal layer K1 
expression would itself significantly inhibit further tumour progression, as introduction of K1, or its 
partner K10, into carcinoma cells reverses the malignant phenotype via enforced differentiation 
(Kartasova et al., 1992; Santos et al., 2002).  
 
Human KA aetiology is also typified by an initial rapid growth phase, followed by arrest and 
regression. In several respects murine HK1.fos/∆5PTENflx KA aetiology mimics that of humans, 
producing a tumour with a highly proliferative papillomatous/carcinoma in situ histotype, underlying 
areas of massive keratosis. However, whether fos/PTENnull synergism drives human KA aetiology 
remains to be confirmed, although fos roles in hyperproliferative disease and keratinocyte 
differentiation/turnover (Angel et al., 2001; Mehic et al., 2005) and the hyperkeratosis following PTEN 
loss (Fistarol et al., 2002; Stambolic et al., 2000; Yao et al., 2006) would be consistent with the 
increased differentiation in KAs. In addition, most human KAs are devoid of p53 mutations and 
exhibit increased p21WAF expression (Ahmed et al., 1997; Perez et al., 1997; Ren et al., 1996). These 
data add fuel to the debate on whether KA represents a differentiated extreme of SCC or a class of 
benign tumour in their own right, with a separate molecular aetiology. Given the contrasting results for 
activated fos or rasHa synergism with PTEN in KA vs. previous SCC aetiology (Yao et al 2006), and the 
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relative lack of typical initiating rasHa or p53 mutations (Ahmed et al., 1997; Lieu et al., 1991; Perez et 
al., 1997; Ren et al., 1996), these murine data suggest a separate molecular aetiology. However, again 
this idea awaits analysis of whether additional/appropriate mutations of rasHa or p53 interdict a murine 
KA aetiology mediated by fos, PTEN and the p53/p21WAF switch.  
 
Initially, p53 status had been assessed in HK1.ras/∆5PTENflx KA aetiology given its well-
characterised roles in skin tumourigenesis (Brash, 2006) and close links with PTEN function where 
PTEN loss invokes p53 loss (Freeman et al., 2003; Wang et al., 2005; Chen et al., 2005), unless 
compensatory mechanisms stabilised p53 (Lei et al., 2006). Hence control K14.cre/∆5PTENflx lost p53 
expression, however resultant hyperplasia was rapidly translated into hyperkeratosis [below]. 
Similarly, hyperplastic HK1.fos epidermis or papillomas were negative for p53 expression, but again 
surveillance systems sensitive to fos-mediated p53 loss were invoked, which maintained a degree of 
normality until promoted (Greenhalgh et al., 1993b), consistent with earlier HK1.fos cooperation 
studies with p53 knockout mice, where HK1.fos/p53null epidermis paradoxically failed to exhibit 
benign tumours (Greenhalgh et al., 1996).  These observations reflect in human photo-carcinogenesis, 
as p53 mutations frequently initiate keratinocytes (Brash, 2006), but tumour aetiology requires 
additional events over time, including UV-induced c-fos-mediated tumour promotion (Gonzales and 
Bowden, 2002; Wang et al., 2005).  
 
Against this background, high levels of p53 expression in basal layers of differentiated, KA histotypes 
was unexpected and identified p53 re-expression to be a key facet underlying a HK1.fos/∆5PTENflx 
KA aetiology. Earlier HK1.fos/∆5PTENflx hyperplasia had exhibited a low-level p53 expression 
response, associated with moderate GSK3β inactivation, which was subsequently lost giving rise to 
the hyperproliferative, p53-negative papillomatous KA histotype with elevated MAP Kinase/cyclin 
D1/E2 activities. Hence when re-expressed in the proliferative basal layers of transitional areas, 
increasing p53 expression abruptly reduced BrdU labelling and K13 expression, and demonstrated 
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that inhibition of tumour progression depended upon both intensity and locality of gene expression 
(Wahl, 2006). In human KAs, p53 expression also becomes increased (Perez et al., 1997) and is 
seldom mutated (Ren et al., 1996), consistent with the lack of p53 or alternate splicing observed in 
HK1.fos/∆5PTENflx KAs, which suggested that normal p53 functions were intact (Nister et al., 2005).  
As with compensatory p53 expression in PTEN-mediated prostate carcinogenesis (Chen et al., 2005; 
Lei et al., 2006), these data predict that a KA aetiology requires fully functional p53 pathways. Hence 
loss of p53 in rasHa/PTEN cooperation or chemical carcinogenesis results in SCC (Suzuki et al., 2003; 
Mao et al., 2004; Yao et al., 2006). Indeed, the relative rarity of human KA compared to SCC may 
reflect the high frequency of UV-B-induced p53 mutations (Brash, 2006) that would interdict this 
putative compensatory mechanism.  
 
High p21WAF expression levels were observed in mature HK1.fos/∆5PTENflx KAs but post the 
appearance of overt benign tumours, as pre-neoplastic or papillomatous histotypes displayed little 
detectable p21WAF and these data suggest that p21WAF inhibited malignant conversion (Topley et al., 
1999). Consistent with this idea, western analysis of p21WAF expression in KAs trailed that of p53 and 
this maybe a consequence of activated AKT expression in papillomatous histotypes [below], as p-
AKT inhibits expression, nuclear localisation and function of p21WAF (Zhou et al., 2001). Logically 
therefore, induction of high p53 re-expression would reduce p-AKT expression (Miyauchi et al., 
2004) and facilitate p21WAF escape from p-AKT inhibition. The resultant basal layer expression of 
p21WAF would reduce proliferation, however p21WAF roles in differentiation, separate to that of cell 
cycle control (Devgan et al., 2006), maybe of greater significance. In normal epidermal 
differentiation, p21WAF expression increases when post-mitotic keratinocytes commit to differentiate 
(Topley et al., 1999; Devgan et al., 2006), echoing the normal keratin K1 expression profile 
(Rothnagel et al., 1993) and suggesting that p21WAF functions in early decisions to commit to terminal 
differentiation. Therefore, high basal layer p21WAF expression would accelerate this commitment to 
differentiate, indicated by basal layer K1 expression, and establish a mechanism that continually 
inhibited progression via terminal differentiation (Kartasova et al., 1992; Topley et al., 1999; Santos et 
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al., 2002). In addition, since p21WAF has both positive and negative roles in keratinocyte 
differentiation, and actually inhibits the latter stages, when p21WAF is normally down regulated 
(Devgan et al., 2006), intense p21WAF expression in each epidermal compartment may explain the 
general disorder to keratinocyte differentiation in HK1.fos/∆5PTENflx KA histotypes, manifest by 
premature loricrin/filaggrin expression and the appearance of micro-cysts, a problem further 
compounded by a increasing lack of p-AKT (Calautti et al., 2005), which would add to the failure to 
down regulate p21WAF function (Devgan et al., 2006; Zhou et al., 2001).  
 
Human KAs also exhibit elevated p21WAF in two distinct patterns; one associated with reduced 
proliferation, one with increased differentiation (Ahmed et al., 1997).  In a tissue continually exposed 
to environmental carcinogens, the ability to exert resistance to tumour progression at each stage is logical 
and may involve common components. In classic ras/myc co-operation, p21WAF induction inhibited 
rasHa-activated skin carcinogenesis in c-myc null cells, until p21WAF was itself compromised by re-
introduction of oncogenic myc (Oskarsson et al., 2006). Similar compensatory effects of p21WAF were 
observed in ∆5PTEN-mediated bladder carcinogenesis, where initial hyperplasia was countered by 
p21WAF expression (Yoo et al., 2006). However, p21WAF expression was not induced in ∆5PTEN-
mediated prostate carcinogenesis (Mulholland et al., 2006), which relied on p53 interactions (Chen et 
al., 2005), whilst the reduced numbers of DMBA/TPA skin tumours in AKT knockout mice was 
independent of p53 (Skeen et al., 2006), highlighting multi-layered redundancies in these systems 
(Wahl, 2006). Perhaps in epithelia concerned with barrier functions, where terminal differentiation to 
eliminate pre-malignant cells is preferable to widespread apoptosis/senescence, induction of p21WAF 
mediated differentiation (Topley et al., 1999; Devgan et al., 2006; Yoo et al., 2006) provides a 
necessary adjunct to p53-mediated apoptosis. 
Regulation of AKT activity was also critical to early phenotypes and the KA tumour outcome. It is 
well accepted that loss of PTEN phosphatase results in elevated AKT activity (Parsons, 2004; 
Downward, 2004) and reduced p53 stability (Freeman et al., 2003; Lei et al., 2006), and AKT 
oncogenicity drives tumour progression in numerous mechanisms (Chen et al 2005; Lei et al 2006; 
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Skeen et al., 2006; Segrelles et al., 2006; Yao et al., 2006). Thus to counterbalance this neoplastic 
potential, early HK1.fos/∆5PTENflx and control phenotypes either down-regulated AKT activity 
(Skeen et al., 2006) or exploited an emerging, anti-apoptotic role in epidermal differentiation that was 
associated with conversion of hyperplasia into hyperkeratosis (Calautti et al., 2005). In p53-negative 
HK1.fos epidermis, p-AKT down regulation helped maintain the differentiation/proliferation balance 
resulting in an overtly normal epidermis. Given recent glioma studies where PTENwt inhibits AP1 
activity via reduced AKT signalling (Koul et al., 2007) and close links between PTEN/p53 loss and 
AP1 status (Wang et al., 2005), PTENwt may act to limit fos-mediated/p53-negative keratinocyte 
proliferation. Hence the lack of p-AKT in hyperplastic HK1.fos epidermis delayed papilloma 
formation, which required TPA/wound promotion (Greenhalgh et al., 1993b, 1995) to induced high p-
ERK 1/2 expression (Karin, 1995; Schlingemann et al., 2003), increase cyclins D1/E2 (Bamberger et 
al., 2001) and restore p-AKT levels (Gonzales and Bowden, 2002).  
 
Alternately in K14.cre/∆5PTEN epidermis, elevated p-AKT expression increased differentiation to 
give hyperkeratosis (Fistarol et al., 2002; Stambolic et al, 2000), consistent with negative roles in 
reduction of endothelial cell lifespan (Miyauchi et al., 2004). In normal epidermis p-AKT expression 
is mainly suprabasal and in vitro its activities prevent p53-mediated apoptosis. This may provide a 
protected interval for keratinocytes to fully commit to terminal differentiation (Calautti et al., 2005). 
In pre-neoplastic K14.cre/∆5PTENflx epidermis, elevated basal cell p-AKT expression disrupted this 
balance and increased proliferation due to concurrent loss of p53/p21WAF cell-cycle regulation. 
However, instead of papillomatogenesis, resultant p-AKT-mediated hyperplasia was rapidly translated 
into hyperkeratosis, suggesting that basal expression of normally suprabasal p-AKT roles induced an 
early differentiation response. If correct, this elegant mechanism thus serves the dual purpose of 
rapidly eliminating potentially highly cancerous cells when PTEN tumour suppressor regulation and 
compensatory p53/p21WAF-mediated apoptosis are interdicted (Brash, 2006), whilst maintaining 
epidermal tissue integrity and barrier functions under pathological conditions such as Cowden disease, 
where PTEN functions in adhesion signalling (Masahito et al., 1998; Subauste et al., 2005) are 
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potentially compromised and cutaneous keratinocytes lack normal p21WAF functions to initiate 
differentiation. 
  
In HK1.fos/∆5PTENflx KA aetiology, initial pre-neoplastic HK1.fos/∆5PTENflx hyperplasia exhibited 
reduced p-AKT expression, alongside low-level p53-feedback, consistent with PTEN loss in prostate 
cancer where compensatory NKX3.1 inhibited p-AKT expression to stabilise p53 (Lei et al., 2006). 
With time increased MAP Kinase signalling and cyclin D1/E2 expression interdicted this early p53 
countermeasure, resulting in high p-AKT expression in p53/p21WAF–negative papillomatous 
histotypes. As outlined above subsequently high p53 co-expression fedback to reduce p-AKT activity 
in basal layers (Lei et al., 2006), inducing increasingly suprabasal p-AKT expression, which in turn 
facilitated basal layer expression of p21WAF (Zhou et al., 2001) and accelerate differentiation. This 
reduction in proliferative basal layer p-AKT expression appeared critical to inhibition of benign 
tumour progression i.e. unless significant p53/p21WAF co-expression induced a basal/suprabasal p-
AKT expression switch to prevent sustained basal layer p-AKT activities, hyperproliferative benign 
tumour keratinocytes would be at risk for conversion, as demonstrated malignant transformation of 
DMBA-initiated, papilloma keratinocytes by introduction of constitutively active AKT (Segrelles et 
al., 2006), possibly via corruption of the anti-apoptotic AKT roles observed in normal differentiation 
(Calautti et al., 2005). 
 
HK1.fos/∆5PTENflx KA aetiology also indicated that a molecular trigger was required to induce basal 
layer p53/p21WAF expression and counter p-AKT/v-fos/PTENnull oncogenicity. A prime candidate for 
this role emerged from analysis of GSK3β status, an unusual serine/threonine kinase where the 
unphosphorylated form is active and complexes with APC to target β-catenin for ubiquitin 
degradation (Karim et al., 2004). This tumour suppression role is inactivated by p-AKT 
phosphorylation, hence p-GSK3β co-operation with PTEN phosphatase loss in prostate carcinogenesis 
(Mulholland et al., 2006), and high p-GSK3β inactivation levels observed in DMBA/TPA carcinomas 
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(Leis et al., 2002) expressing elevated p-AKT activation (Segrelles et al., 2006). However, GSK3β 
status influences carcinogenesis in pathways separate to AKT, as pools of activated/inactivated 
GSK3β are interchangeable between PI3K/AKT and WNT/β-catenin pathways (Karim et al., 2004; 
Mulholland et al., 2006). Accordingly, while p-GSK3β inactivation paralleled p-AKT expression in 
p53-negative K14.cre/∆5PTENflx and early HK1.fos hyperplasia, moderate p-GSK3β inactivation 
levels, uncoupled from p-AKT expression were observed in pre-neoplastic HK1.fos/∆5PTENflx 
hyperplasia [and HK1.fos papillomas]. This moderate p-GSK3β expression appeared alongside low-
level p53 expression, consistent with induction of p53 following GSK3β inactivation in colon 
carcinogenesis (Ghosh and Altieri, 2005). However, low-level p-GSK3β expression induced neither 
high p53 nor p21WAF expression, therefore HK1.fos/∆5PTENflx hyperplasia was susceptible to MAP 
kinase/cyclin D1/E2-associated promotion, resulting in restored, elevated basal layer p-AKT 
expression in the p53/p21WAF-negative papillomatous histotypes [above], somewhat akin to the 
mechanism of p-AKT activation/p-GSK3β inactivation observed in fos-mediated [p53-null] HaCaT 
photo-carcinogenesis (Gonzales and Bowden, 2002).  
 
As levels of p-GSK3β expression increased, possibly from a combination of moderate p-AKT-
independent expression, observed in HK1.fos/∆5PTENflx hyperplasia and that derived from increasing 
p-AKT expression during papillomatogenesis; it achieved a threshold of GSK3β inactivation that 
triggered the high, sustained p53/p21WAF response. Again a key component centred on the switch of 
moderate, suprabasal p-GSK3β expression in papillomatous histotypes to one of high basal expression 
in transitional areas that induced p53, reduced p-AKT and initiated p21WAF-mediated differentiation 
[above]. This attractive scenario thus explains why induction of high p53, and p21WAF in particular, 
abruptly appeared in benign tumours, as the mechanism required substantial increases in p-GSK3β 
expression. Temporal GSK3β inactivation thus provided the sensory component of the mechanism 
geared to induce compensatory p53/p21WAF responses, that actually required/exploited HK1.fos/p-
AKT synergism in papillomatogenesis, yet continually blocked further progression. As this GSK3β-
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associated mechanism of compensatory p53/p21WAF may also induce apoptosis in alternate tumours 
(Ghosh and Altieri, 2005; Miyauchi et al., 2004; Yoo et al., 2006), it makes GSK3β inhibitors 
attractive for therapeutic intervention (Smalley et al., 2007; Tan et al., 2005). However, this should be 
approached with caution, given that GSK3β-inactivated inhibition of skin tumour progression directly 
contrasts with GSK3β-inactivated co-operation with PTEN loss that accelerates prostate 
carcinogenesis (Mulholland et al., 2006). Hence, potential efficacy may require tumor aetiologies 
where intact p53/p21WAF response pathways (Nister et al., 2005; Wahl, 2006) can be induced (Smalley 
et al., 2007; Tan et al., 2005), as chemical carcinogenesis (Leis et al., 2002) and alternate models of 
AKT activation (Segrelles et al., 2006) show that should p53 and/or p21WAF pathways become 
compromised, GSK3β inhibition could prove to be a double-edged sword.  
 
In summary, this HK1.fos/∆5PTENflx model links PTEN/PI3K/AKT signalling, ras/MAPK/fos 
pathways and the GSK3β/β-catenin/WNT axis and demonstrates that when deregulated by fos 
activation and/or PTEN loss, benign tumour progression can be inhibited by induction of p53 and/or 
p21WAF pathways that limit oncogenic AKT activities. Collectively, these findings highlight the worth 
of inducible, transgenic models that allow mice to develop normally and thus yield valuable insights 
into the molecular relationships regulating normal tissue homeostasis.  This carcinogenesis study also 
stressed the importance of context to the biological outcome of temporal, stage-specific gene 
expression, where common molecular expression profiles combined to give an unanticipated outcome 
that provides new insights into the capacity of the epidermis to cope with specific oncogenic insults. 
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METHODS 
 
 Genotypes, transgene expression and RU486 treatment.  
HK1.fos (Greenhalgh et al., 1993b), RU486-inducible K14.creP regulator (Berton et al., 2000) and 
∆5PTENflx (Li et al., 2002) transgenic mice have been characterized previously. Breeding strategies 
maintained HK1.fos and K14.creP transgenes as heterozygotes in wild type [PTENwt], heterozygous 
[∆5PTENwt/flx] or homozygous [∆5PTENflx] PTEN backgrounds respectively. PTEN exon 5 ablation 
was achieved via activation of cre recombinase in dorsal skin treated topically with 2 ug RU486 in 
50ul ethanol/week [mefipristone, Sigma] for 4 weeks, with controls receiving ethanol alone [UK 
License: 60/2929 to DAG]. HK1.fos, K14.creP and ∆5PTEN mice were genotyped by PCR and 
expression confirmed via rt/PCR (Greenhalgh et al., 1993a; Yao et al., 2006). For detection of p53 or 
c-ras
Ha
 mutations, tumour DNA was isolated as described (Yao et al., 2006), amplified with intron-
specific oligonucleotides and sequenced. 
 
Histology, Immunefluorescence and Bromo-deoxyuridine Labelling Analysis 
Skin and tumour biopsies were fixed [10% formalin, 4oC] and stained with haematoxylin and eosin, or 
frozen in OCT [Miles] and stored at -70°C. For immunefluorescence, frozen sections (5-7µm) were 
incubated overnight with:  rabbit anti-K13 (Prof. D. Roop, Houston), anti-K1, anti-loricrin, anti-
filaggrin [diluted 1:500] (Cambridge Bioscience) or guinea pig anti-K14 antibodies [dil 1:2000] 
(Research Diagnostics) and visualized by biotinylated goat anti-guinea pig/Streptavidin-Texas Red 
[diluted 1:100] (Vector Labs) or FITC-labelled anti-rabbit IgG [diluted 1:100; Jackson Labs]. For 
BrdU labelling, mice were injected IP with 125 mg/kg 5-bromo-4-deoxyuridine [Sigma] 2 hours prior 
to biopsy. Paraffin sections were subjected to antigen retrieval [10 mins boil/10mM sodium citrate] 
and BrdU labelling performed by overnight incubation at 40C with FITC-conjugated anti-BrdU dil 
1:50 [Becton Dickinson], counterstained for K14 (above). For immunohistochemical analysis, 
sections were incubated with phospho-GSK3β(ser9) #9936 and phospho-AKT(273) #9271 [Cell Signaling 
Technology];  p53 (PAB 240) [CRUK Antibodies]; and p21WAF [#sc397, Santa Cruz] overnight [dil 1-
28 
100/biotin-anti-goat 1:50) [Santa Cruz]; and visualized via HRP-conjugated strepavidin, incubated for 
5 mins at room temp. 
 
Western Analysis 
Proteins were extracted from biopsy tissue as described (Yao et al., 2006). Proteins were subjected to 
western analysis employing antibodies to: total AKT #9272; phospho-AKT #9271, phospho-ERK 
#9101, total ERK p42/44 #9102, cyclin D1 #2922, cyclin E2 #4132, GSK3β #9315 and phospho 
GSK3β(ser9) #9936 [Cell Signaling Technology]; p53 (PAB 240) [CRUK Antibodies];  p21WAF #sc397 
and β-actin #sc1616 [Santa Cruz]. Signals were detected with HRP-conjugated secondary antibodies 
(Dako) and ECL detection (Amersham Biosciences). 
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LEGENDS 
 
 
Figure 1. Phenotype and histotype of HK1.fos/∆5PTENflx mice. 
Upper panel: RU486-treated homozygous and heterozygous HK1.fos-∆5PTENflx mice exhibit ear 
keratoacanthomas [KAs]. Control HK1.fos siblings possess small papillomas and RU486-treated 
K14.cre/∆5PTENflx mice exhibit hyperkeratosis. Lower panel:  [A] RU486-treated HK1.fos skin 
histology was indistinguishable from normal. [B] K14.cre/∆5PTENflx epidermis exhibits mild 
hyperplasia, significant hyperkeratosis and ghost cells indicative of incorrect cornification. [C] 
HK1.fos papillomas histology displays expanded epidermal compartments but an overall ordered 
keratinocyte differentiation pattern. [D] A composite HK1.fos/∆5PTENflx KA micrograph displays two 
distinct histotypes: an upper, differentiated area of massive keratosis interspaced with fronds of 
keratinocytes and a lower hyperproliferative, papilloma-like region. [E] HK1.fos/∆5PTENflx KA 
keratinocytes of differentiated regions display a distinct disorder to the programme of differentiation, 
with cornified and granular cells co-existing alongside basal layer keratinocytes [arrows]. [F] Such 
regions also exhibited a prominent stratum lucidium [arrows] and [G] premature differentiation gave 
rise to micro-cysts. [Bars: A-C 100 µm; E-G 50 µm; and D approx. 175 µm]. 
 
Figure 2: Expression of differentiation markers in HK1.fos/∆5PTEN tumours.  
 
[A] HK1.fos papillomas exhibit a delay in onset of suprabasal keratin K1 expression [green] consistent 
with expansion of the proliferative basal cell compartment, counterstained with K14 [red]. 
HK1.fos/∆5PTENflx KAs exhibit strong, atypical K1 expression in proliferative basal cells of 
differentiated regions [no separate K14/red is visible], suggesting an accelerated terminal 
differentiation. [B] Late-stage differentiation markers loricrin and [C] filaggrin remained confined to 
the granular layer in HK1.fos papillomas. In contrast, HK1.fos/∆5PTENflx KAs display premature, 
elevated loricrin and filaggrin expression indicative of an accelerated disordered nature to 
differentiation e.g. loricrin in micro-cysts. [D] HK1.fos papillomas expressed tumor progression 
J 
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marker keratin K13, which was focally expressed in papillomatous HK1.fos/∆5PTENflx areas, whereas 
K13 expression was lost in differentiated KA histotypes 
 
Figure 3: HK1.fos/∆5PTEN synergism increases mitotic index in papillomatogenesis until KA is 
achieved.  
Upper panel: Tabulated mitotic index from HK1.fos/∆5PTEN epidermis and tumors. Despite a normal 
histotype, HK1.fos epidermis possessed a 2-fold increase in mitotic index over normal epidermis, 
similar to that of hyperkeratotic [HK] K14.cre/∆5PTENflx epidermis. This index further doubled in 
HK1.fos/∆5PTEN hyperplastic/hyperkeratotic [HPK] epidermis to levels observed in overt HK1.fos 
papillomas. The lower average mitotic labelling in HK1.fos/∆5PTEN KAs comprised a low mitotic index 
in differentiated vs. a very high index in papillomatous histotypes. Lower panel: Double label BrdU 
immunefluorescence analysis of mitotic activity. Differentiated HK1.fos/∆5PTENflx KA histotypes show 
low BrdU labelling [yellow] similar to that found in HK1.fos papillomas, conversely, papillomatous areas 
exhibit very high BrdU labelling.  
 
Figure 4. Expression of p53, p-AKT, p-GSK3β and p-ERK 1/2 in HK1.fos/∆5PTEN phenotypes.  
 
Skin biopsies of keratoacanthomas [KA], papillomas [PAP], hyperplastic [HP] or hyperkeratotic [HK] 
epidermis, together with normal dorsal [N], anagen [aN] or ear skin [NE] were subject to western 
analysis. All HK1.fos/∆5PTEN KAs expressed high p53 levels and phenotypic epidermis possessed 
low-level expression [mid panel] similar to normal controls [end panel]. Conversely, p53 expression 
was undetectable in HK1.fos phenotypes [lanes: PAP, HP, N] or hyperkeratotic K14.cre/∆5PTENflx 
epidermis [end panel]. HK1.fos/∆5PTEN KAs expressed high but variable p-GSK3β levels, depending 
on tumour maturity [∆5PTEN heterozygous KA #8898 vs. homozygous KA # 9593]. However, KAs 
exhibited lower increases in p-AKT expression, which varied extensively with the degree of keratosis 
[Ka*]. Compared to total protein levels, HK1.fos epidermis exhibited low p-AKT and p-GSK3β 
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expression [first panel]; whilst p-GSK3β expression, but not p-AKT, increased in HK1.fos papillomas. 
Control K14.cre/∆5PTENflx epidermis possessed elevated p-GSK3β and p-AKT expression [end 
panel]. All hyperplastic phenotypes expressed elevated p-ERKs 1 and 2, including “normal” HK1.fos 
epidermis and HK1.fos papillomas in particular, which remained steady, if slightly reduced, in all 
KAs. β-actin expression served as a loading control. 
 
 
Figure 5: HK1.fos/∆5PTEN KAs exhibit high p53 and novel p21WAF expression associated with a 
threshold level of GSK3β inactivation.   
 
Western analysis of p53, p-GSK3β and p-AKT was compared to p21WAF, cyclin D1 and E2 
expression in pathology matched KAs [similar keratosis/papilloma ratios] and age matched 
preneoplastic phenotypes. Hyperkeratotic [HK] K14.cre/∆5PTENflx ear epidermis displayed little 
detectable p21WAF or p53 and slightly increased expression of p-AKT, cyclins D1 and E2, with p-
GSK3β being higher in the tagged [T], wound-promoted biopsy. Normal [N] appearing HK1.fos 
epidermis was negative for p21WAF and p53 expression, with low p-GSK3β and decreased p-AKT 
levels, alongside slightly elevated cyclin D1. HK1.fos papillomas [PAP] expressed little p21WAF and 
p53, but displayed increased p-GSK3β expression compared to p-AKT, together with elevated 
cyclins. HK1.fos/∆5PTENflx epidermis [HK] expressed barely detectable p21WAF, limited p53 and 
moderate p-GSK3β expression, whilst p-AKT expression was less than K14.cre/∆5PTENflx controls. 
All HK1.fos/∆5PTENflx KAs expressed high levels of p21WAF and p53 that mirrored significant 
increases in p-GSK3β inactivation. However, p-AKT expression remained similar to 
K14.cre/∆5PTENflx epidermis. All KAs exhibited elevated cyclin D1 and E2 expression, particularly 
in ear-tagged samples [KAT].  β-actin served as a loading control. 
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Figure 6:  Immunohistochemical analysis of p53, p21WAF, p-GSK3β and p-AKT expression in 
differentiated and proliferative HK1.fos/∆5PTEN KA histotypes.  
 
[A-C] p53 expression in differentiated [A], transitional [B] and papillomatous [C] KA histotypes. 
Note high, basal layer p53 expression in [A], was increasing in [B] from suprabasal to basal and 
absent in [C] papillomatous areas [Composite micrographs and immunohistochemical analysis of 
control HK1.fos and K14.cre/∆5PTENflx phenotypes are shown  in Supp data Figs. 2 and 3]. [D-F] 
Similarly strong basal p21WAF expression was observed in differentiated KA histotypes [D] which had 
increased and become nuclear in transitional areas [E], but was absent in papillomatous histotypes [F]. 
[G-I] Strong, basal layer p-GSK3β expression in differentiated KA areas [G] preceded that of p53/p21 
in transitional areas [H] and was observed in papillomatous areas [I], where lower expression was 
confined to suprabasal layers. [J-L] Conversely, in differentiated KA areas p-AKT expression was 
reduced, cytoplasmic and undetectable in basal layers [J]; a process that began in transitional areas 
where expression became increasingly suprabasal and faded [K], unlike strong expression observed in 
papillomatous histotypes [L]. [Magnification bars: A and J: 25 µm; D and G: 50 µm; remainder: 
100µm]. 






  
      
Figure 1S: Upper panel: reverse transcriptase/PCR analysis of HK1.fos expression 
identifies an approx 700bp v-fos–specific band in:  non-phenotypic normal HK1.fos adult 
skin [lane N; N*: w/o reverse transcriptase control for DNA contamination]; and RU486-
treated HK1.fos/∆5PTEN flx or HK1.fos/∆5PTEN het  KAs.  
 
Lower panel: ∆5PTEN expression in:  Untreated skin [lanes 1 and 2] and RU486-treated 
skin from HK1.fos/∆5PTEN Het [lanes 3,4] or HK1.fos/∆5PTEN flx [lanes 5,6] identify a 
∆5PTEN floxed allele-specific band [approx 1100bp], the wt allele [900bp] and the truncated 
∆5PTEN floxed allele-specific band following exon 5 ablation in treated keratinocytes 
[400bp]. 
 
 
 
 
  
        
 
       
 
 
          
 
Figure 2S: Composite micrographs of protein expression in HK1.fos/∆5PTENflx 
keratoacanthomas.   
Adjacent sections are those shown in Fig. 6 and in each composite the left panel/area shows the 
proliferative, papillomatous histotype while the right displays differentiated, frond regions. 
Both p53 and p21WAF exhibit little expression in the papillomatous areas, however strong, 
increasingly basal layer expression appeared in differentiated/keratotic areas, with p21WAF 
expression appearing in both cytoplasm and nucleus. p-GSK3β expression increased in 
papillomatous histotypes prior to the p53/p21 expression burst, but this expression remained 
essentially suprabasal; whereas in differentiated histotypes, a further increase and basal layer p-
GSK3β expression was observed. Conversely, an inverse relationship was recorded for p-AKT 
expression. Strong expression in papillomatous regions faded in the corresponding p53/p21WAF-
expressing differentiated histotypes. A more subtle finding in transitional areas demonstrated 
that strong p-AKT co-expression produced a less intense and suprabasal p53/p21WAF expression 
profile and vice versa, increasing p53/p21WAF expression produced less intense and suprabasal 
p-AKT co-expression, until p- AKT expression faded [Mag.  Bar: 150 um].  
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 Figure 3S: Immunohistochemical analysis of p53, p21WAF, p-GSK3β and p-AKT 
expression in HK1.fos and K14.cre/∆5PTEN histotypes.  
HK1.fos and K14.cre/∆5PTEN sections are from control siblings age matched to those 
shown in Fig. 6 and Supp. Fig 2S. In both HK1.fos papillomas and K14.cre/∆5PTEN 
epidermal hyperplasia, p53 and p21WAF expression were consistently negative, as were 
normal and hyperplastic HK1.fos epidermis [not shown]. In normal or early hyperplastic 
HK1.fos epidermis, p-GSK3β levels were low [not shown], whereas in later 
hyperplasias/early papillomas, p-GSK3β expression increased to detectable levels, which 
remained suprabasal and similar but below to papillomatous HK1.fos/∆5PTEN histotypes 
[Fig. 6I]. Conversely, hyperplastic HK1.fos epidermis possessed very little p-AKT 
expression, which remained low in papillomas [not shown]. Hyperplastic 
K14.cre/∆5PTEN epidermis displayed strong p-AKT expression in each epidermal 
compartment including basal layers and follicles, yet no papillomas appeared and 
hyperkeratosis was the predominant histotype. This was mirrored by p-GSK3β in being a 
downstream target of AKT, but p-GSK3β expression was mainly suprabasal and below 
that observed in HK1.fos/∆5PTEN KAs [Fig. 6] [mag. Bars 50 or 100 um]. 
